Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth

Ehrbar, Martin; Djonov, Valentin G.; Schnell, Christian; Tschanz, Stefan A.; Martiny-Baron, Georg; Schenk, Ursula; Wood, Jeanette; Burri, Peter H.; Hubbell, Jeffrey A.; Zisch, Andreas H. (2004). Cell-demanded liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. Circulation research, 94(8), pp. 1124-1132. Lippincott Williams & Wilkins 10.1161/01.RES.0000126411.29641.08

[img] Text
1124.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Although vascular endothelial growth factor (VEGF) has been described as a potent angiogenic stimulus, its application in therapy remains difficult: blood vessels formed by exposure to VEGF tend to be malformed and leaky. In nature, the principal form of VEGF possesses a binding site for ECM components that maintain it in the immobilized state until released by local cellular enzymatic activity. In this study, we present an engineered variant form of VEGF, alpha2PI1-8-VEGF121, that mimics this concept of matrix-binding and cell-mediated release by local cell-associated enzymatic activity, working in the surgically-relevant biological matrix fibrin. We show that matrix-conjugated alpha2PI1-8-VEGF121 is protected from clearance, contrary to native VEGF121 mixed into fibrin, which was completely released as a passive diffusive burst. Grafting studies on the embryonic chicken chorioallantoic membrane (CAM) and in adult mice were performed to assess and compare the quantity and quality of neovasculature induced in response to fibrin implants formulated with matrix-bound alpha2PI1-8-VEGF121 or native diffusible VEGF121. Our CAM measurements demonstrated that cell-demanded release of alpha2PI1-8-VEGF121 increases the formation of new arterial and venous branches, whereas exposure to passively released wild-type VEGF121 primarily induced chaotic changes within the capillary plexus. Specifically, our analyses at several levels, from endothelial cell morphology and endothelial interactions with periendothelial cells, to vessel branching and network organization, revealed that alpha2PI1-8-VEGF121 induces vessel formation more potently than native VEGF121 and that those vessels possess more normal morphologies at the light microscopic and ultrastructural level. Permeability studies in mice validated that vessels induced by alpha2PI1-8-VEGF121 do not leak. In conclusion, cell-demanded release of engineered VEGF121 from fibrin implants may present a therapeutically safe and practical modality to induce local angiogenesis.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Anatomy
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Anatomy > Anatomy

UniBE Contributor:

Tschanz, Stefan A.

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0009-7330

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Beatrice Itten

Date Deposited:

13 Jan 2014 15:53

Last Modified:

13 Jul 2015 14:50

Publisher DOI:

10.1161/01.RES.0000126411.29641.08

PubMed ID:

15044320

Uncontrolled Keywords:

therapeutic angiogenesis, vascular endothelial growth factor, fibrin, controlled release

BORIS DOI:

10.7892/boris.39817

URI:

https://boris.unibe.ch/id/eprint/39817

Actions (login required)

Edit item Edit item
Provide Feedback